Molecular Diagnosis of P53 Mutations in Gastric Carcinoma by Touch Preparation

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 1996 Feb 1

PMID 8579104

Citations 4

Authors

E Ricevuto

C Ficorella

C Fusco

K Cannita

A Tessitore

E Toniato

A Gabriele

L Frati

P Marchetti

A Gulino

S Martinotti

Affiliations

Soon will be listed here.

Abstract

Thirty-one tumor samples from selected cases of gastric carcinoma were analyzed for mutations of the p53 tumor suppressor gene. Template DNA was prepared according to the touch preparation procedure, which allowed us to isolate clusters of neoplastic cells out of a stromal cellular background to be used as a template in the amplification of target exons of the p53 locus. In our present study, by polymerase chain reaction/single strand conformation polymorphism analysis we give evidence of p53 mutations occurring in the DNA-binding core domain of the protein (exons 5 through 9), which are clustered in stages III and IV of the disease (six mutations out of seventeen samples; 35%). No p53 mutations were detected in fourteen gastric cancer samples at I and II stages. Beside the use of conventional molecular scanning procedures, our study proposes the application of the touch preparation method to increase the detection of genetic alterations in human solid tumors.

Citing Articles

Tumor Touch Imprints as Source for Whole Genome Analysis of Neuroblastoma Tumors.

Brunner C, Brunner-Herglotz B, Ziegler A, Frech C, Amann G, Ladenstein R PLoS One. 2016; 11(8):e0161369.

PMID: 27560999 PMC: 4999140. DOI: 10.1371/journal.pone.0161369.

Sensitivity to cisplatin in primary cell lines derived from human glioma correlates with levels of EGR-1 expression.

Calogero A, Porcellini A, Lombari V, Fabbiano C, Arcella A, Miscusi M Cancer Cell Int. 2011; 11:5.

PMID: 21366897 PMC: 3059282. DOI: 10.1186/1475-2867-11-5.

Inhibition of cell growth by EGR-1 in human primary cultures from malignant glioma.

Calogero A, Lombari V, De Gregorio G, Porcellini A, Ucci S, Arcella A Cancer Cell Int. 2004; 4(1):1.

PMID: 14711380 PMC: 324562. DOI: 10.1186/1475-2867-4-1.

K-ras point mutations in the supernatants of pancreatic juice and bile are reliable for diagnosis of pancreas and biliary tract carcinomas complementary to cytologic examination.

Yamashita K, Kida Y, Shinoda H, Kida M, Okayasu I Jpn J Cancer Res. 1999; 90(2):240-8.

PMID: 10189896 PMC: 5926043. DOI: 10.1111/j.1349-7006.1999.tb00739.x.

References

Kurtin P, Pinkus G . Leukocyte common antigen--a diagnostic discriminant between hematopoietic and nonhematopoietic neoplasms in paraffin sections using monoclonal antibodies: correlation with immunologic studies and ultrastructural localization. Hum Pathol. 1985; 16(4):353-65. DOI: 10.1016/s0046-8177(85)80229-x. View

LAUREN P . THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand. 1965; 64:31-49. DOI: 10.1111/apm.1965.64.1.31. View

Hirohashi S, Sugimura T . Genetic alterations in human gastric cancer. Cancer Cells. 1991; 3(2):49-52. View

Sano T, Tsujino T, Yoshida K, Nakayama H, Haruma K, Ito H . Frequent loss of heterozygosity on chromosomes 1q, 5q, and 17p in human gastric carcinomas. Cancer Res. 1991; 51(11):2926-31. View

Tamura G, Kihana T, Nomura K, Terada M, Sugimura T, Hirohashi S . Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorphism analysis. Cancer Res. 1991; 51(11):3056-8. View

Loeb L . Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 1991; 51(12):3075-9. View

Levine A, Momand J, Finlay C . The p53 tumour suppressor gene. Nature. 1991; 351(6326):453-6. DOI: 10.1038/351453a0. View

Kern S, Kinzler K, Bruskin A, Jarosz D, Friedman P, Prives C . Identification of p53 as a sequence-specific DNA-binding protein. Science. 1991; 252(5013):1708-11. DOI: 10.1126/science.2047879. View

Gaidano G, Ballerini P, Gong J, Inghirami G, Neri A, Newcomb E . p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 1991; 88(12):5413-7. PMC: 51883. DOI: 10.1073/pnas.88.12.5413. View

10.

Kim J, Takahashi T, Chiba I, Park J, Birrer M, Roh J . Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines. J Natl Cancer Inst. 1991; 83(13):938-43. DOI: 10.1093/jnci/83.13.938. View

11.

Kovach J, McGovern R, Cassady J, Swanson S, Wold L, Vogelstein B . Direct sequencing from touch preparations of human carcinomas: analysis of p53 mutations in breast carcinomas. J Natl Cancer Inst. 1991; 83(14):1004-9. DOI: 10.1093/jnci/83.14.1004. View

12.

Yamada Y, Yoshida T, Hayashi K, Sekiya T, Yokota J, Hirohashi S . p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases. Cancer Res. 1991; 51(21):5800-5. View

13.

Kastan M, Onyekwere O, Sidransky D, Vogelstein B, Craig R . Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991; 51(23 Pt 1):6304-11. View

14.

Serra A, Gaidano G, Revello D, Guerrasio A, Ballerini P, Dalla Favera R . A new TaqI polymorphism in the p53 gene. Nucleic Acids Res. 1992; 20(4):928. PMC: 312060. DOI: 10.1093/nar/20.4.928. View

15.

Martin H, FILIPE M, Morris R, Lane D, Silvestre F . p53 expression and prognosis in gastric carcinoma. Int J Cancer. 1992; 50(6):859-62. DOI: 10.1002/ijc.2910500604. View

16.

Oliner J, Kinzler K, Meltzer P, GEORGE D, Vogelstein B . Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992; 358(6381):80-3. DOI: 10.1038/358080a0. View

17.

Matozaki T, Sakamoto C, Suzuki T, Matsuda K, Uchida T, Nakano O . p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells. Cancer Res. 1992; 52(16):4335-41. View

18.

Vogelstein B, Kinzler K . p53 function and dysfunction. Cell. 1992; 70(4):523-6. DOI: 10.1016/0092-8674(92)90421-8. View

19.

Lin D, Shields M, Ullrich S, Appella E, Mercer W . Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc Natl Acad Sci U S A. 1992; 89(19):9210-4. PMC: 50095. DOI: 10.1073/pnas.89.19.9210. View

20.

Kastan M, Zhan Q, El-Deiry W, Carrier F, Jacks T, Walsh W . A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 1992; 71(4):587-97. DOI: 10.1016/0092-8674(92)90593-2. View